| Literature DB >> 24381771 |
Abimbola Aderinto1, Vibav Mouli1, Danielle F Resar1, Linda M S Resar2.
Abstract
We report a challenging case of a 16-year-old male who presented with thrombocytopenia and eluded a definitive diagnosis for over 2 years. He was initially diagnosed with a viral illness, although he later developed adenopathy and splenomegaly. An evaluation by an oncologist was unrevealing. He worked on a farm with livestock exposure and was later diagnosed with an atypical, zoonotic infection. Despite appropriate antibiotic therapy, the thrombocytopenia and splenomegaly persisted. Further evaluation revealed that he has a relatively common immunologic disorder. He is currently doing well on appropriate therapy for this disorder.Entities:
Year: 2013 PMID: 24381771 PMCID: PMC3870096 DOI: 10.1155/2013/153767
Source DB: PubMed Journal: Case Rep Hematol ISSN: 2090-6579
Figure 1Abdominal ultrasound demonstrating lymphadenopathy and splenomegaly. (a) The lymph node diameter (3.1 cm) is demarcated by the arrows. (b) The spleen dimensions (18.3 cm × 9.3 cm) are demarcated by the arrows.
Clinical manifestations of Q fever [1–6].
| Symptoms | Karagiannis et al., 2009 [ | Sampere et al., 2003 [ | Raoult et al., 2000 [ | Domingo et al., 1999 [ | Tselentis et al., 1995 [ |
Tissot Dupontet al., 1992 [ |
Average ( |
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| Fever | 25% | 84% | 91% | 100% | 92% | 82% | 87% |
| Hepatitis | 33% | 62% | 48% | 52% | 60% | ||
| Malaise | 39% | 33% | 62% | 48% | 52% | 53% | 58% |
| Headache | 41% | 42% | 51% | 56% | 50% | ||
| Chills | 29% | 59% | 44% | ||||
| Pulmonary involvement | 22% | 56% | 34% | 41% | 89% | 38% | 38% |
| Myalgia/arthralgia | 9% | 41% | 37% | 46% | 36% | ||
| Thrombocytopenia | 35% | 35% | |||||
| Cough | 37% | 27% | 35% | 33% | |||
| Hepatomegaly | 24% | 54% | 22% | 31% | |||
| GI symptoms | 27% | 19% | 16% | 18% | |||
| Splenomegaly | 22% | 11% | 16% | ||||
| Weight loss | 11% | 11% | |||||
| Rash | 11% | 2% | 2% | 21% | 12% | ||
| Lymphadenopathy | 7% | 7% | |||||
| Palpitations | 4% | 4% | |||||
| Neurological symptoms | 1% | 12% | 9% | 3% | |||
| Jaundice | 2% | 2% | |||||
| Myocarditis | 1% | 1% | |||||
| Pericarditis | 1% | 1% |
Clinical manifestations of CVID [8–13].
| Symptoms | Chapel et al., 2008 [ | Oksenhendler et al., 2008 [ | Quinti et al., 2007 [ | Cunningham-Rundles and Bodian, 1999 [ | Hermaszewski and Webster, 1993 [ | Cunningham-Rundles, 1989 [ | Average |
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| Sinusitis, otitis media, bronchitis, and mastoiditis | 69% | 86% | 98% | 36% | 100% | 75% | |
| Pneumonia | 58% | 49% | 79% | 63% | 87% | 69% | |
| Bronchiectasis | 25% | 37% | 18% | 27% | |||
| Splenomegaly | 30% | 38% | 13% | 27% | |||
| Liver disease | 17% | 17% | |||||
| Diarrhea | 23% | 23% | 6% | 12% | 16% | ||
| Lymphadenopathy | 15% | 5% | 11% | ||||
| Urogenital infection | 7% | 7% | 7% | ||||
| Granulomatous disease | 8% | 14% | 3% | 8% | 1% | 7% | |
| Thrombocytopenia | 7% | 6% | 6% | 3% | 6% | 7% | |
| Non-Hodgkin's lymphoma | 3% | 2% | 8% | 8% | 5% | ||
| Herpes/varicella | 4% | 7% | 2% | 5% | |||
| Hepatomegaly | 9% | 1% | 5% | ||||
| Hemolytic anemia | 4% | 3% | 5% | 3% | 5% | 4% | |
| Pernicious anemia | 9% | 1% | 2% | 1% | 4% | ||
| Hepatitis | 2% | 7% | 1% | 12% | 4% | ||
| Meningitis/encephalitis | 8% | 1% | 1% | 7% | 4% | 4% | |
| Sepsis | 13% | 1% | 1% | 2% | 4% | ||
| Malaise | 3% | 3% | |||||
| Crohn's disease | 2% | 4% | 1% | 3% | |||
| Vitiligo | 5% | 2% | 2% | 3% | |||
| Atopic dermatitis | 2% | 2% | |||||
| Osteomyelitis | 1% | 3% | 1% | 2% | |||
| Autoimmune neutropenia | 1% | 3% | 1% | 2% | |||
| Stomach cancer | 2% | 1% | 2% | 2% | |||
| Septic arthritis | 2% | 1% | 4% | 1% | 2% | ||
| Psoriasis | 2% | 1% | 1% | ||||
| Oral candidiasis | 2% | 1% | 1% | 1% | |||
| Parotitis | 1% | 1% | 1% |
Genes implicated in CVID [7, 10].
| Gene symbol | Protein encoded | Protein function | Chromosomal location | Estimated % CVID patients | Reference |
|---|---|---|---|---|---|
|
| CD19 | Protein component of the B-cell receptor complex | 16p | <1% | Chapel et al., 2008 [ |
|
| |||||
|
| Inducible costimulator of activated T-cells | Expressed on activated T-cells; facilitates cooperation between B and T-cells | 2q | 2% | Cunningham-Rundles, 2010 [ |
|
| |||||
|
| Transmembrane activator and calcium-modulator and cyclophilin ligand (TACI) | Induces activation of transcription factors (NFAT, AP1, and NF-kappaB) and plays a crucial role in humoral immunity by interacting with a TNF ligand | 17p | 8% | Cunningham-Rundles, 2010 [ |
|
| |||||
|
| BAFF-R, B-cell activating factor of the TNF family receptor | B-cell receptor specific for B-cell-activating factor (BAFF) which enhances B-cell survival | 22q | Unknown | Chapel et al., 2008 [ |
|
| |||||
|
| MSH5 | Involved in DNA mismatch repair or meiotic recombination processes | 6p | 12% | Chapel et al., 2008 [ |
|
| |||||
|
| MS4A1 | Encodes a B-lymphocyte surface molecule involved in development and differentiation of B-cells into plasma cells | 11q12-q13 | <1% | Cunningham-Rundles, 2010 [ |
|
| |||||
|
| CD81 (TAPA1) | Mediates signal transduction events involved in regulating cell development, growth, and motility | 11p15.5 | <1% | Cunningham-Rundles, 2010 [ |